https://www.selleckchem.com/pr....oducts/seclidemstat.
Limited experimental and clinical evidence suggests a potential role for sofosbuvir/daclatasvir in treating COVID19. We aim to evaluate the efficacy of generic sofosbuvir/daclatasvir in treating COVID-19 patients with pneumonia. This multicenter prospective study involved 174 patients with COVID-19. Patients were randomized into two groups. Group A (96 patients) received sofosbuvir (400 mg)/daclatasvir (60 mg) for 14days in combination with conventional therapy. Group B (78 patients) received conventional therapy alone. Clinical, l
Like
Comment
Share
